---
title: "Definium net loss more than doubled to $159 million in Q2 FY26"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295137106.md"
description: "Definium Therapeutics reported a Q2 FY26 net loss of $159 million, more than doubling from the prior year's $42.7 million, primarily due to an $86.2 million non-cash warrant liability revaluation. R&D and G&A expenses also increased significantly. The company raised $805 million via public offering, boosting cash reserves to $1.1 billion with a runway into 2030. Additionally, Definium announced positive Phase 3 Emerge results for MDD, with further data expected in August and September."
datetime: "2026-08-06T20:05:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295137106.md)
  - [en](https://longbridge.com/en/news/295137106.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295137106.md)
---

# Definium net loss more than doubled to $159 million in Q2 FY26

-   Definium Therapeutics posted a Q2 net loss of $159 million versus $42.7 million a year earlier, driven by an $86.2 million non-cash warrant liability revaluation. \* R&D expense rose to $48.7 million from $29.8 million, while G&A climbed to $26.4 million from $11.1 million. \* Cash, cash equivalents and investments totaled about $1.1 billion at June 30, up from $411.6 million at Dec. 31, 2025; cash runway seen into 2030. \* Completed a public offering raising $805 million in gross proceeds; net proceeds were about $757.9 million. \* Reported positive Phase 3 Emerge topline results in MDD; Phase 3 Voyage GAD data due the week of Aug. 10, with Panorama GAD data expected in September. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608061601BIZWIRE\_USPR\_\_\_\_\_20260806\_BW201575) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)

## Related News & Research

- [What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120?](https://longbridge.com/en/news/295821556.md)
- [Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo](https://longbridge.com/en/news/295787298.md)
- [Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'](https://longbridge.com/en/news/295680444.md)
- [Definium Therapeutics publishes corporate presentation outlining DT120 ODT clinical development pipeline in mental health indications](https://longbridge.com/en/news/295840904.md)
- [Definium says LSD-based pill reduces anxiety in late-stage study](https://longbridge.com/en/news/295653550.md)